Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,296Revenue $M580Net Margin (%)-117.4Altman Z-Score12.2
Enterprise Value $M29,950EPS $-3.1Operating Margin %-108.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-117.0Higher ROA y-yN
Price/Book30.810-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales49.15-y EBITDA Growth Rate %--Current Ratio4.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-62.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M244ROIC % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 124.294%Reduce 2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 124.294%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 124.294%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 124.2910%Reduce 16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 124.2931%Reduce 31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 124.2977%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 124.2978%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 124.2978%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 124.2957%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 124.2957%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 124.2979%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 124.2956%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 124.2969%Add 140.58%5,990,000
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 124.2969%Sold Out0
VRTXVanguard Health Care Fund 2013-03-31 Add0.05%$43.65 - $54.97
($48.01)
$ 124.29159%Add 10.97%2,489,800
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 124.29159%Reduce 23.44%191,032
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 124.29132%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 124.29132%Sold Out0
VRTXNWQ Managers 2012-06-30 Reduce-0.27%$35.75 - $65.62
($50.92)
$ 124.29144%Reduce 83.86%188,842
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 124.29144%New holding20,025
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2015-06-24Sell11,700$130.41-6.43view
BOGER JOSHUA SDirector 2015-06-17Sell11,700$123.9-1.51view
BOGER JOSHUA SDirector 2015-06-10Sell11,700$125.02-2.39view
BOGER JOSHUA SDirector 2015-06-03Sell11,700$125.81-3view
MCGLYNN MARGARET GDirector 2015-06-01Sell12,500$127.32-4.15view
BOGER JOSHUA SDirector 2015-05-27Sell11,700$126.08-3.21view
BOGER JOSHUA SDirector 2015-05-20Sell11,700$126.73-3.71view
Arbuckle Stuart AEVP\Chief Commercial Officer 2015-05-15Sell148$123.85-1.47view
SMITH IAN FEVP & CFO 2015-05-15Sell378$125.62-2.86view
Silva Paul MSVP & Corp Controller 2015-05-15Sell135$123.85-1.47view

Quarterly/Annual Reports about VRTX:

News about VRTX:

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week Jun 29 2015
Acquisitions May Fuel Gilead Sciences' Winning Ways Jun 26 2015
Here are the nine highest-paid life science executives in 2014 (BBJ photo gallery) Jun 26 2015
Biotech leads Nasdaq to fresh record close Jun 18 2015
Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors Jun 18 2015
Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors Jun 18 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Change in Directors or Principal Officers Jun 12 2015
Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT Jun 12 2015
The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE... Jun 11 2015
Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference Jun 11 2015
Vertex Double Downs on Cystic Fibrosis Jun 10 2015
'Spending On These 10 Drugs Could Cost Taxpayers $50 Billion'--Is That Bad For Patients? Jun 10 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 09 2015
10 drugs to hit fed budget by $50B over decade Jun 08 2015
Vertex's $1B deal with Parion expands interest into other kinds of CF drugs Jun 08 2015
Durham's Parion inks deal that could exceed $1 billion Jun 08 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC)... Jun 04 2015
VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 04 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK